News

Andrés Bratt-Leal, a co-founder of Aspen Neuroscience who is leading work there on a potential stem cell therapy for Parkinson’s disease, is among the recipients of the 2023 Life Science Catalyst Award given to young scientists and entrepreneurs in recognition of their contributions. Sponsored by…

Some molecular changes that drive damage to brain cells in Parkinson’s disease take place in skin cells too, a study has found, adding to evidence that examining the skin may support an early diagnosis. Because skin cells are much easier to collect than brain cells, they also could be…

The first patient has been dosed in a Phase 2 clinical trial testing AC Immune’s ACI-7104.056, an investigational vaccine targeting toxic alpha-synuclein forms to prevent nerve cell degeneration in Parkinson’s disease. AC Immune expects to complete the enrollment of the first group of patients in the VacSYn…

The Institute for Glial Sciences, a center dedicated to the role of glial cells in Parkinson’s disease and others affecting the nervous system with a goal of better treatments, is opening at Case Western Reserve University in Ohio. It will be led by Paul Tesar, PhD, a professor in…

U.K. scientist Dario Alessi, PhD, has been named the winner of the 2023 Robert A. Pritzker Prize for Leadership in Parkinson’s Research — awarded annually by the Michael J. Fox Foundation (MJFF) to a researcher who makes exceptional contributions in the field of Parkinson’s disease and seeks…

Buntanetap significantly reduced the levels of TDP-43 protein in the blood of people with Parkinson’s disease who participated in a Phase 2a clinical trial, according to clinical data from its developer Annovis Bio. The treatment also demonstrated a trend toward reducing other markers of inflammation. “We are pleasantly…

A Phase 1/2 clinical trial testing AAV-GAD, an investigational gene therapy being developed by MeiraGTx for Parkinson’s disease, is expected to be fully enrolled before the end of the year, the company announced in a press release. The placebo-controlled trial (NCT05603312), which began dosing last…

A five-year project funded by a $3.9 million National Institutes of Health (NIH) research grant will study how team-based palliative care might lead to better health services and ease disparities in Parkinson’s disease and disease-related dementia care. Palliative care focuses on improving the quality of life for individuals with…

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded a $10 million grant to Octave Biosciences to advance the development and validation of a protein biomarker panel assay for Parkinson’s disease. A biomarker assay for multiple proteins could offer a better tool to monitor and…

In what is being touted as an “historic” act, the spouse and children of qualified veterans with Parkinson’s disease, or those with the disease themselves, are invited to apply for assistance under the Camp Lejeune Family Member Program (CLFMP) run by the U.S. Department of Veteran Affairs…